Why Real-World Evidence Is Important for Real-World Cancer Patients

Posted by Jon Roffman on Jun 24, 2019 9:44:47 AM

“A lot of clinical trials are a bit artificial in that the eligibility criteria are ‘purple and pink polka dot patients,’ [but those patients] really don't exist.”

That was the start of my conversation with Dr. Julie Vose at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, where we sat down to talk about real-world evidence and its importance in oncology. Dr. Vose is a believer in evidence-based medicine, and real-world evidence is an important tool in her arsenal for making treatment decisions at the University of Nebraska Medical Center, where she is the head of hematology and oncology.


>
Read More

Precision Medicine Comes Into View With the Use of Next-Generation Sequencing

Posted by Jon Roffman on Jun 27, 2018 8:00:00 AM

Marie Yurkovich and Olivia Tang-Kong co-authored this post with Jon Roffman.

Precision medicine in cancer care has been anticipated and talked about for years. The ability to classify a patient based on her tumor’s molecular changes and then treat her with the right targeted therapy is a concept that gives hope to the many men, women and children diagnosed with cancer. Given recent advancements, there’s good reason for this hope.


>
Read More

Attention Oncology Manufacturers: Customer Experience Matters

Posted by Jon Roffman on Apr 4, 2016 8:00:00 AM

What’s the experience that we want our customers to have? It’s a simple question, really, so why isn’t it front and center for marketing and sales people at oncology companies? Perhaps because being in the business of providing life-extending medicines to cancer patients, we would believe that should result in a positive customer experience. We’d at least expect an experience that’s better than, say, the next iPhone or a visit to the Magic Kingdom, and yet when you look at the Net Promoter Score for oncology manufacturers, the experience that they deliver lags woefully behind that of Apple and Disney. In fact, based on a recent research study conducted by ZS, we see that most oncology manufacturers have a negative Net Promoter Score, meaning that more of their customers have a negative experience than a positive one.


>
Read More